IL163475A - 4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1- f][1,2,4]triazin-2-yl) benzene-sulfonyl chloride, process for its preparation and uses thereof - Google Patents

4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1- f][1,2,4]triazin-2-yl) benzene-sulfonyl chloride, process for its preparation and uses thereof

Info

Publication number
IL163475A
IL163475A IL163475A IL16347504A IL163475A IL 163475 A IL163475 A IL 163475A IL 163475 A IL163475 A IL 163475A IL 16347504 A IL16347504 A IL 16347504A IL 163475 A IL163475 A IL 163475A
Authority
IL
Israel
Prior art keywords
dihydroimidazo
triazin
oxo
ethoxy
benzene
Prior art date
Application number
IL163475A
Other languages
Hebrew (he)
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL163475(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE19750085A external-priority patent/DE19750085A1/en
Priority claimed from DE1998112462 external-priority patent/DE19812462A1/en
Priority claimed from DE1998140289 external-priority patent/DE19840289A1/en
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of IL163475A publication Critical patent/IL163475A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL163475A 1997-11-12 2004-08-12 4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1- f][1,2,4]triazin-2-yl) benzene-sulfonyl chloride, process for its preparation and uses thereof IL163475A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19750085A DE19750085A1 (en) 1997-11-12 1997-11-12 New 2-phenyl-imidazotriazinone derivatives used for treating cardiovascular, cerebrovascular and urogenital disorders
DE1998112462 DE19812462A1 (en) 1998-03-23 1998-03-23 New phosphodiesterase inhibiting 2-phenyl-imidazotriazinone derivatives useful for treating e.g. cardiovascular, cerebrovascular and/or urogenital diseases
DE1998140289 DE19840289A1 (en) 1998-09-04 1998-09-04 New phosphodiesterase inhibiting 2-phenyl-imidazotriazinone derivatives useful for treating e.g. cardiovascular, cerebrovascular and/or urogenital diseases
PCT/EP1998/006910 WO1999024433A1 (en) 1997-11-12 1998-10-31 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
IL163475A true IL163475A (en) 2015-11-30

Family

ID=27217917

Family Applications (3)

Application Number Title Priority Date Filing Date
IL13546298A IL135462A0 (en) 1997-11-12 1998-10-31 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
IL135462A IL135462A (en) 1997-11-12 2000-04-04 PHOSPHODIESTERASE INHIBITING 1 - ETHOXY - 2 - [5-METHYL- 4[3H] OXO - 7 - PROPYLIMIDAZO [5,1 - f] [1,2,4]TRIAZIN - 2 - YL] BENZENE- 4 - SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IL163475A IL163475A (en) 1997-11-12 2004-08-12 4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1- f][1,2,4]triazin-2-yl) benzene-sulfonyl chloride, process for its preparation and uses thereof

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL13546298A IL135462A0 (en) 1997-11-12 1998-10-31 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
IL135462A IL135462A (en) 1997-11-12 2000-04-04 PHOSPHODIESTERASE INHIBITING 1 - ETHOXY - 2 - [5-METHYL- 4[3H] OXO - 7 - PROPYLIMIDAZO [5,1 - f] [1,2,4]TRIAZIN - 2 - YL] BENZENE- 4 - SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Country Status (44)

Country Link
US (9) US6362178B1 (en)
EP (3) EP2295436A1 (en)
JP (2) JP3356428B2 (en)
KR (2) KR100430355B1 (en)
CN (2) CN100430396C (en)
AR (2) AR013759A1 (en)
AT (1) ATE213246T1 (en)
AU (1) AU738675B2 (en)
BG (1) BG65257B1 (en)
BR (2) BR9816155B1 (en)
CA (2) CA2395558C (en)
CH (1) CH693954A5 (en)
CO (1) CO4980861A1 (en)
CU (1) CU23063A3 (en)
CY (1) CY1112949T1 (en)
CZ (1) CZ301911B6 (en)
DE (3) DE59803108D1 (en)
DK (3) DK1174431T3 (en)
EE (1) EE04781B1 (en)
ES (3) ES2172945T3 (en)
FI (1) FI113772B (en)
GB (1) GB2346877B (en)
HK (2) HK1031730A1 (en)
HN (1) HN1998000175A (en)
HR (2) HRP20000292B1 (en)
HU (3) HU230154B1 (en)
ID (1) ID25871A (en)
IL (3) IL135462A0 (en)
IN (1) IN188419B (en)
LU (1) LU90561B1 (en)
MY (1) MY138535A (en)
NO (2) NO314940B1 (en)
NZ (1) NZ504436A (en)
PE (1) PE131799A1 (en)
PL (2) PL194801B1 (en)
PT (2) PT1049695E (en)
SE (1) SE522809C2 (en)
SI (2) SI1049695T1 (en)
SK (1) SK287161B6 (en)
TR (1) TR200001338T2 (en)
TW (2) TWI229081B (en)
UA (1) UA46166C2 (en)
UY (2) UY25246A1 (en)
WO (1) WO1999024433A1 (en)

Families Citing this family (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
HU230154B1 (en) * 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Process for the preparation of 2-phenyl substituted imidazotriazinones
DE19827640A1 (en) 1998-06-20 1999-12-23 Bayer Ag New imidazotriazine derivatives useful as smooth muscle relaxants for treating e.g. cardiovascular disorders, cerebrovascular disorders, or erectile dysfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
DE19944161A1 (en) * 1999-09-15 2001-03-22 Bayer Ag New combination for the treatment of sexual dysfunction
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
US20050070499A1 (en) * 1999-11-08 2005-03-31 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
IL139455A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
US6777416B2 (en) 1999-12-24 2004-08-17 Bayer Aktiengesellschaft Isoxazolo pyrimidinones and the use thereof
JP2003519151A (en) * 1999-12-24 2003-06-17 バイエル アクチェンゲゼルシャフト Triazolotriazinones and their use
CN1434825A (en) 1999-12-24 2003-08-06 拜尔公司 Novel imidazo[1,3,5]riazinones and the use thereof
DE10010067A1 (en) 2000-03-02 2001-09-06 Bayer Ag New 2-phenyl-imidazo (5,1-f) (1,2,4) triazin-4-one derivatives, are phosphodiesterase inhibitors useful for treating cardiovascular, cerebrovascular or urogenital disorders
JP2004500425A (en) 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー Use of cyclic GMP-specific phosphodiesterase inhibitors for the treatment of Parkinson's disease
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
CN1478084A (en) * 2000-09-29 2004-02-25 Compounds useful in treatment of inflammatory diseases
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20020091129A1 (en) * 2000-11-20 2002-07-11 Mitradev Boolell Treatment of premature ejaculation
DE10063106A1 (en) * 2000-12-18 2002-06-20 Bayer Ag Process for the preparation of 2- (2-ethoxyphenyl) substituted imidazotriazinones
DE10063108A1 (en) * 2000-12-18 2002-06-20 Bayer Ag Process for the preparation of sulfonamide-substituted imidazotriazinones
DE10064105A1 (en) * 2000-12-21 2002-06-27 Bayer Ag New substituted imidazotriazinones
AU2002226633A1 (en) 2001-02-02 2002-08-12 Pfizer Limited Treatment of diabetes mellitus using vardenafil
DE10107639A1 (en) * 2001-02-15 2002-08-22 Bayer Ag 2-alkoxyphenyl substituted imidazotriazinones
DE10108752A1 (en) * 2001-02-23 2002-09-05 Bayer Ag New substituted imidazotriazinones
GB0107751D0 (en) * 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
DE10118306A1 (en) 2001-04-12 2002-10-17 Bayer Ag Composition for intranasal administration of imidazo-triazinone derivative cGMP PDE inhibitor for treatment of erectile dysfunction, also containing local anesthetic to prevent nasal blockage and improve absorption
JP4540295B2 (en) * 2001-05-09 2010-09-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト New uses for 2-phenyl substituted imidazotriazinones
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US7087605B2 (en) 2001-06-01 2006-08-08 Bayer Aktiengesellschaft 5-Ethyl-imidazotriazinones
GB0113344D0 (en) 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
DE10130167A1 (en) 2001-06-22 2003-01-02 Bayer Ag imidazotriazines
DE10135815A1 (en) * 2001-07-23 2003-02-06 Bayer Ag Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain
EP1421084B1 (en) 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
US6943171B2 (en) 2001-11-09 2005-09-13 Schering Corporation Polycyclic guanine derivative phosphodiesterase V inhibitors
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
DE60222931T2 (en) * 2001-12-13 2008-07-10 Asubio Pharma Co., Ltd. PYRAZOLOPYRIMIDINONE DERIVATIVES WITH PDE7-HEMMENDER EFFECT
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
GB0209988D0 (en) * 2002-05-01 2002-06-12 Bayer Ag Novel Heterocycles
DE10220570A1 (en) 2002-05-08 2003-11-20 Bayer Ag Carbamate-substituted pyrazolopyridines
US7091207B2 (en) 2002-05-22 2006-08-15 Virginia Commonwealth University Method of treating myocardial infarction with PDE-5 inhibitors
AU2003223071A1 (en) * 2002-05-23 2003-12-12 Pfizer Inc. Pharmaceutical combination of PDE5 inhibitors with ACE inhibitors
SI1509525T1 (en) 2002-05-31 2006-12-31 Schering Corp Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
DE10229778A1 (en) * 2002-07-03 2004-01-29 Bayer Ag New use of imidazotriazinones
DE10230605A1 (en) 2002-07-08 2004-01-29 Bayer Ag Substituted imidazotriazines
DE10232113A1 (en) * 2002-07-16 2004-01-29 Bayer Ag Medicinal products containing vardenafil hydrochloride trihydrate
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
WO2004087652A2 (en) 2003-04-01 2004-10-14 Smithkline Beecham Corporation Imidazotriazine compounds
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
EP1625334B9 (en) 2003-05-21 2012-07-25 Alexza Pharmaceuticals, Inc. Percussively ignited self-contained heating unit
JP2006528229A (en) 2003-05-22 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト Composition containing PDE4 inhibitor and PDE5 inhibitor
CN100374441C (en) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 2-substituted benzyl-5,7-dihydrocarbyl-3,7-dihydro pyrroline [2,3-d] pyromidine-4-one derivative ,its preparation and medicinal use
JP2006219374A (en) * 2003-06-13 2006-08-24 Daiichi Asubio Pharma Co Ltd Imidazotriazinone derivative having pde 7 inhibition
US20050079548A1 (en) * 2003-07-07 2005-04-14 Plexxikon, Inc. Ligand development using PDE4B crystal structures
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
PE20050985A1 (en) * 2003-11-21 2005-11-26 Schering Corp FORMULATIONS OF PHOSPHODIESTERASE V INHIBITORS
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
US7449462B2 (en) 2004-01-22 2008-11-11 Pfizer, Inc. Triazole derivatives which inhibit vasopressin antagonistic activity
EP1742950B1 (en) * 2004-04-07 2008-12-17 Pfizer Limited Pyrazolo[4,3-d] pyrimidines
DE102004023069A1 (en) * 2004-05-11 2005-12-08 Bayer Healthcare Ag New dosage forms of the PDE 5 inhibitor vardenafil
JP2008501617A (en) * 2004-06-11 2008-01-24 アスビオファーマ株式会社 Imidazotriazinone derivatives having PDE7 inhibitory action
DE102005001989A1 (en) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenous formulations of PDE inhibitors
KR20080016531A (en) * 2005-02-18 2008-02-21 서피스 로직스, 인크. Pharmacokinetically improved compounds
EP1848437A4 (en) * 2005-02-18 2012-04-25 Surface Logix Inc Methods of making pharmacokinetically improved compounds comprising functional residues or groups and pharmaceutical compositions comprising said compounds
DE102005009240A1 (en) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with improved pharmacokinetic properties
DE102005009241A1 (en) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with controlled bioavailability
DE102005016345A1 (en) * 2005-04-09 2006-10-12 Bayer Healthcare Ag New use of 2-phenyl-substituted imidazotriazinone derivatives
MX2007012711A (en) 2005-04-19 2008-01-11 Nycomed Gmbh Roflumilast for the treatment of pulmonary hypertension.
NZ564187A (en) 2005-05-12 2010-03-26 Pfizer Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2006127368A2 (en) * 2005-05-20 2006-11-30 Lexicon Genetics Incorporated Methods for synthesizing imidazotriazinones
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
SG166106A1 (en) 2005-09-29 2010-11-29 Bayer Schering Pharma Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1984347A1 (en) * 2006-02-17 2008-10-29 Wyeth a Corporation of the State of Delaware Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
AR059518A1 (en) * 2006-02-17 2008-04-09 Wyeth Corp METHODS TO PREPARE SUBSTITUTED ALCOHOLS WITH SULFONAMIDS AND THEIR INTERMEDIATE COMPOUNDS
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7977478B2 (en) * 2006-03-13 2011-07-12 Dr. Reddy's Laboratories Limited Polymorphic forms of vardenafil
EP3124471B1 (en) * 2006-03-17 2020-06-03 The Johns Hopkins University N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US20080027072A1 (en) * 2006-04-20 2008-01-31 Ampla Pharmaceuticals, Inc. Potentiation of MC4 receptor activity
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
PL2032521T3 (en) 2006-06-27 2010-05-31 Sandoz Ag New method for salt preparation
WO2008008398A2 (en) * 2006-07-14 2008-01-17 Shionogi & Co., Ltd. Oxime compounds and the use thereof
US20100324037A1 (en) * 2006-08-24 2010-12-23 Surface Logix, Inc. Pharmacokinetically improved compounds
AR062501A1 (en) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd THERAPEUTIC COMPOSITIONS
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
DE102006043443A1 (en) * 2006-09-15 2008-03-27 Bayer Healthcare Ag Novel aza-bicyclic compounds and their use
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
AU2007333115B2 (en) 2006-12-12 2013-01-10 Gilead Sciences, Inc. Composition for treating a pulmonary hypertension
SG178775A1 (en) 2007-02-12 2012-03-29 Dmi Biosciences Inc Reducing side effects of tramadol
US20080194529A1 (en) * 2007-02-12 2008-08-14 Auspex Pharmaceuticals, Inc. HIGHLY SELECTIVE and LONG-ACTING PDE5 MODULATORS
MX2009008491A (en) 2007-02-12 2010-01-20 Dmi Biosciences Inc Treatment of comorbid premature ejaculation and erectile dysfunction.
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
DE102007027067A1 (en) 2007-06-12 2008-12-18 Ratiopharm Gmbh Process for the preparation of a medicament containing vardenafil hydrochloride trihydrate
WO2008151734A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
CN101965348B (en) * 2007-09-06 2013-11-13 上海特化医药科技有限公司 Process for preparing vardenafil and intermediates thereof
BRPI0722222A2 (en) * 2007-12-28 2015-06-16 Topharman Shangai Co Ltd N- {1- [3- (2-ethoxy-5- (4-ethylpiperazinyl) sulfonylphenyl) -4,5-dihydro-5-oxo-1,2,4-triazin-6-yl] ethyl} butyramide, its preparation method and its use
WO2009091777A1 (en) * 2008-01-15 2009-07-23 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
DE102008063992A1 (en) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. New aliphatic substituted pyrazolopyridines and their use
EP2379076B1 (en) 2008-12-23 2014-11-12 The Trustees of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009020888A1 (en) 2009-05-12 2010-11-18 Ratiopharm Gmbh Orodispersible tablet containing a vardenafil salt
US20120190849A1 (en) 2009-08-07 2012-07-26 Ranbaxy Laboratories Limited Processes for the preparation of vardenafil
PE20121742A1 (en) * 2009-11-27 2012-12-13 Adverio Pharma Gmbh PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINE-2- [1- (2-FLUOROBENZYL) -1H-PIRAZOLO [3,4-b] PYRIDIN-3-IL] PYRIMIDIN-5-IL} METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
UY33041A (en) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINO-2- [1- (2-FLUOROBENCIL) -1H-PIRAZOLO [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} CARBAMATO DE METTILO AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
WO2011075801A1 (en) 2009-12-21 2011-06-30 Acef S.A. Cubebin, dibenzylbutyrolactone lignan, semi-synthetic and synthetic derivatives thereof, and other lignans and neolignans as vasodilating agents in the therapy of erectile dysfunction
PL390079A1 (en) 2009-12-30 2011-07-04 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Process for the preparation of vardenafil and its isolation as a salt with citric acid and a crystalline form of this salt
KR101377178B1 (en) 2010-04-05 2014-03-26 에스케이케미칼주식회사 PDE5 inhibitor-containing composition for improving skin wrinkle
DE102010021637A1 (en) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituted 5-fluoro-1H-pyrazolopyridines and their use
CN102372730B (en) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 Bridged ring substituted phosphodiesterase inhibitor
CN102382129B (en) * 2010-08-19 2014-02-26 山东轩竹医药科技有限公司 Spirocycles-substituted phosphodiesterase inhibitor
JP5855109B2 (en) 2010-09-20 2016-02-09 フォーラム・ファーマシューティカルズ・インコーポレイテッドＦｏｒｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． Imidazotriazinone compounds
AU2011305462B2 (en) 2010-09-23 2015-11-26 Abbvie Bahamas Ltd. Monohydrate of an azaadamantane derivative
TWI542580B (en) 2010-10-15 2016-07-21 基利科學股份有限公司 Compositions and methods of treating pulmonary hypertension
TWI462739B (en) 2010-11-02 2014-12-01 Univ Kaohsiung Medical Processes for preparing piperazinium salts of sildenafil-analogues and use thereof
CN102134242B (en) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 Novel compounds for quickly treating impotence with long-lasting action
CN106905324B (en) 2011-10-10 2018-09-25 H.隆德贝克有限公司 PDE9 inhibitor with Imidazopyrazines ketone skeleton
AT512084A1 (en) * 2011-10-20 2013-05-15 Univ Wien Tech DIAZABICYCLO AND DIAZASPIRO ALKAN DERIVATIVES AS PHOSPHODIESTERASE-5 INHIBITORS
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
CZ2011767A3 (en) * 2011-11-24 2013-06-05 Zentiva, K.S. Processfor preparing and isolation of acid vardenafil salts
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
CN104168895B (en) 2012-02-28 2020-02-21 首尔制药株式会社 Bitter taste-masking high-content fast-dissolving film comprising sildenafil as active ingredient
EP2828262A4 (en) 2012-03-19 2015-09-23 Forum Pharmaceuticals Inc Imidazotriazinone compounds
CN103374002B (en) * 2012-04-19 2015-07-15 山东轩竹医药科技有限公司 Phosphodiesterase-5 inhibitor
CZ307091B6 (en) 2012-09-14 2018-01-10 Zentiva, K.S. A stable pharmaceutical preparation containing Vardenafil hydrochloride
EP2929886B1 (en) 2012-12-04 2021-11-24 Aribio Inc. Composition comprising phosphodiesterase type 5 inhibitor for inhibiting apoptosis of nerve cells
KR101953735B1 (en) 2012-12-14 2019-03-04 한미약품 주식회사 Chewable tablet comprising a phosphodiesterase-5 inhibitor
MX2015010725A (en) 2013-02-21 2016-05-31 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3, 4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate.
CN104109164B (en) * 2013-04-18 2016-05-25 广州朗圣药业有限公司 A kind of preparation method who is applicable to industrialized high-purity hydrochloric acid Vardenafil trihydrate
US10899756B2 (en) 2013-07-17 2021-01-26 The Trustees Of Columbia University In The City Of New York Phosphodiesterase inhibitors and uses thereof
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
PL223869B1 (en) * 2013-12-16 2016-11-30 Starogardzkie Zakłady Farm Polpharma Spółka Akcyjna Method for obtaining Vardenafil and its salts
KR101645652B1 (en) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 Sexual function improvement composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient
DK3303339T3 (en) 2015-07-07 2021-04-12 H Lundbeck As PDE9 INHIBITORS WITH THE IMIDAZOTRIAZINON SKELELINE AND IMIDAZOPYRAZINON SKELELINE FOR THE TREATMENT OF PERIOD DISEASES
MX2018005239A (en) 2015-11-16 2019-09-04 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof.
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
KR102670626B1 (en) 2017-05-22 2024-05-29 토파두르 파마 아게 Novel dual mode of action of soluble guanylate cyclase activator and phosphodiesterase inhibitor and use thereof
CN107445964A (en) * 2017-07-29 2017-12-08 合肥创新医药技术有限公司 A kind of synthetic method of Vardenafil hydrochloric acid impurity
RU2020123526A (en) 2017-12-20 2022-01-20 Клария Фарма Холдинг Аб FILM COMPOSITION CONTAINING VARDENAFIL, METHOD FOR ITS PRODUCTION AND APPLICATION
JP2021526134A (en) 2018-05-25 2021-09-30 イマラ インク． 6-[(3S, 4S) -4-methyl-l- (pyrimidine-2-ylmethyl) pyrrolidine-3-yl] -3-tetrahydropyran-4-yl-7H-imidazole [l, 5-A] pyrazine- 8-one monohydrate and crystalline form
CA3103716A1 (en) 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
EP3807897A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for treating erectile dysfunction with a cgmp-specific phosphodiesterase 5 inhibitor pharmaceutical composition
BR112021009958A2 (en) * 2018-11-28 2021-08-17 Topadur Pharma Ag dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and their uses
EP3939954A4 (en) 2019-03-13 2023-01-04 Otsuka Pharmaceutical Co., Ltd. Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
PE20240248A1 (en) * 2020-12-11 2024-02-19 Ildong Pharmaceutical Co Ltd NEW COMPOUNDS AS A DUAL INHIBITOR OF THE ANDROGEN RECEPTOR AND PHOSPHODIESTERASE
CN114085225A (en) * 2021-06-04 2022-02-25 广东西捷药业有限公司 Vardenafil analogue and synthetic method and application thereof
AU2022354094A1 (en) 2021-09-29 2024-02-15 Topadur Pharma Ag Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
KR20230129639A (en) 2022-03-02 2023-09-11 연세대학교 산학협력단 A dual mode of action PDE5 inhibitor/organic nitrate ester in a transdermal dosage form to increase local blood flow
WO2023166013A1 (en) 2022-03-02 2023-09-07 Topadur Pharma Ag Topical compositions and uses therof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US26565A (en) * 1859-12-27 Improved register for railroad-cars
DE812845C (en) 1944-12-07 1951-09-06 Georges Lissac glasses
US2705715A (en) 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (en) 1957-11-27 1963-02-28 Ciba Geigy Process for the production of new sulfonamides
GB1042471A (en) 1963-01-16 1966-09-14 Ilford Ltd Penta-azaindenes, their production and use in photographic emulsions
GB1051734A (en) 1963-01-16
US3169129A (en) 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
USRE26565E (en) 1966-03-02 1969-04-29 Table iii
GB1493685A (en) 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
GB1338235A (en) 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
BE791025A (en) 1971-11-19 1973-05-07 Allen & Hanburys Ltd HETEROCYCLIC COMPOUNDS
GB1457873A (en) 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
GB1584461A (en) 1977-03-25 1981-02-11 Allen & Hanburys Ltd Imidazotriazines imidazotriazinones and pharmaceutical compositions containing them
DK109578A (en) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd PROCEDURE FOR MAKING HETEROCYCLIC COMPOUNDS
US4308384A (en) 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
US4287673A (en) * 1980-01-11 1981-09-08 Sunbeam Corporation Hair dryer diffuser
DE3166627D1 (en) 1980-12-12 1984-11-15 Thomae Gmbh Dr K Pyrimidones, their preparation and medicines containing them
US4431440A (en) 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS60246396A (en) 1984-05-22 1985-12-06 Sankyo Co Ltd Enzyme-inhibiting substance dihydrodesoxy griseolic acid and its salt
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
CA1303037C (en) 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
DE68908786T2 (en) 1988-06-16 1994-03-17 Smith Kline French Lab Condensed pyrimidine derivatives, processes and intermediates for their preparation and pharmaceutical preparations containing them.
GB8814352D0 (en) 1988-06-16 1988-07-20 Smith Kline French Lab Chemical compounds
US5075310A (en) 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
GB8928346D0 (en) 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
ATE121619T1 (en) * 1990-04-11 1995-05-15 Upjohn Co METHOD FOR TASTE COVERING IBUPROFEN.
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9119704D0 (en) * 1991-09-14 1991-10-30 Pfizer Ltd Therapeutic agents
GB9121028D0 (en) * 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
GB9312210D0 (en) 1993-06-14 1993-07-28 Smithkline Beecham Plc Chemical compounds
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
EP0669324A4 (en) 1993-09-10 1996-04-03 Eisai Co Ltd Quinazoline compound.
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5374053A (en) * 1994-01-21 1994-12-20 Heidelberger Druckmaschinen Ag Device for changing the transport position of products
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
HU230154B1 (en) * 1997-11-12 2015-09-28 Bayer Intellectual Property Gmbh Process for the preparation of 2-phenyl substituted imidazotriazinones
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
DE19827640A1 (en) * 1998-06-20 1999-12-23 Bayer Ag New imidazotriazine derivatives useful as smooth muscle relaxants for treating e.g. cardiovascular disorders, cerebrovascular disorders, or erectile dysfunction
UA67802C2 (en) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
CA2323008C (en) * 1999-10-11 2005-07-12 Pfizer Inc. Pharmaceutically active compounds
CN1434825A (en) * 1999-12-24 2003-08-06 拜尔公司 Novel imidazo[1,3,5]riazinones and the use thereof
JP4540295B2 (en) * 2001-05-09 2010-09-08 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト New uses for 2-phenyl substituted imidazotriazinones
DE10232113A1 (en) * 2002-07-16 2004-01-29 Bayer Ag Medicinal products containing vardenafil hydrochloride trihydrate

Also Published As

Publication number Publication date
KR20040014591A (en) 2004-02-14
NZ504436A (en) 2001-08-31
HRP20020585A2 (en) 2005-10-31
UA46166C2 (en) 2002-05-15
PT1174431E (en) 2012-07-24
US7696206B2 (en) 2010-04-13
ES2194567B1 (en) 2005-03-01
CN100430396C (en) 2008-11-05
SE0001745D0 (en) 2000-05-11
US20130059844A1 (en) 2013-03-07
CA2309332C (en) 2002-12-03
AU1558799A (en) 1999-05-31
CU23063A3 (en) 2005-07-19
TWI229081B (en) 2005-03-11
US6566360B1 (en) 2003-05-20
EP2295436A1 (en) 2011-03-16
CN1278822A (en) 2001-01-03
DE19881732C1 (en) 2002-01-31
JP2001522851A (en) 2001-11-20
CY1112949T1 (en) 2016-04-13
NO20002444D0 (en) 2000-05-11
CA2309332A1 (en) 1999-05-20
AR035972A2 (en) 2004-07-28
CA2395558C (en) 2007-07-17
US7704999B2 (en) 2010-04-27
KR100430355B1 (en) 2004-05-04
PL194801B1 (en) 2007-07-31
US20100016323A1 (en) 2010-01-21
NO20021714D0 (en) 2002-04-11
US6362178B1 (en) 2002-03-26
BG65257B1 (en) 2007-10-31
PE131799A1 (en) 1999-12-30
DE59803108D1 (en) 2002-03-21
NO20021714L (en) 2000-05-11
EP1174431A3 (en) 2002-01-30
GB0010974D0 (en) 2000-06-28
HRP20000292A2 (en) 2001-04-30
IL135462A0 (en) 2001-05-20
BR9812785A (en) 2000-10-10
TR200001338T2 (en) 2000-08-21
EE200000291A (en) 2001-06-15
IN188419B (en) 2002-09-21
DK1174431T3 (en) 2012-08-20
NO20002444L (en) 2000-05-11
HUP0100394A2 (en) 2001-09-28
US20110009367A1 (en) 2011-01-13
EP1174431B1 (en) 2012-05-30
HU228196B1 (en) 2013-01-28
ATE213246T1 (en) 2002-02-15
CN1508137A (en) 2004-06-30
DK200000766A (en) 2000-05-09
SE522809C2 (en) 2004-03-09
EE04781B1 (en) 2007-02-15
CH693954A5 (en) 2004-05-14
ES2172945T3 (en) 2002-10-01
FI20001086A (en) 2000-05-09
TW513431B (en) 2002-12-11
CN1123573C (en) 2003-10-08
US7122540B2 (en) 2006-10-17
BG104406A (en) 2001-08-31
SI1049695T1 (en) 2002-06-30
SK7092000A3 (en) 2001-03-12
HUP0100394A3 (en) 2002-05-28
SK287161B6 (en) 2010-02-08
AU738675B2 (en) 2001-09-20
EP1174431A2 (en) 2002-01-23
JP3356428B2 (en) 2002-12-16
HRP20000292B1 (en) 2008-09-30
BR9816155B1 (en) 2010-07-27
HK1031730A1 (en) 2001-06-22
GB2346877B (en) 2001-12-05
WO1999024433A1 (en) 1999-05-20
SE0001745L (en) 2000-05-11
DK1049695T3 (en) 2002-05-13
AR013759A1 (en) 2001-01-10
PT1049695E (en) 2002-07-31
DE19881732D2 (en) 2000-08-24
IL135462A (en) 2006-04-10
EP1049695B1 (en) 2002-02-13
CZ301911B6 (en) 2010-07-28
ID25871A (en) 2000-11-09
HN1998000175A (en) 1999-01-08
US20060189615A1 (en) 2006-08-24
HK1067124A1 (en) 2005-04-01
FI113772B (en) 2004-06-15
CO4980861A1 (en) 2000-11-27
NO314940B1 (en) 2003-06-16
EP1049695A1 (en) 2000-11-08
LU90561B1 (en) 2000-12-01
US7314871B2 (en) 2008-01-01
UY25246A1 (en) 2001-08-27
US20080113972A1 (en) 2008-05-15
GB2346877A (en) 2000-08-23
JP2002348290A (en) 2002-12-04
ES2194567A1 (en) 2003-11-16
KR20010031944A (en) 2001-04-16
ES2386420T3 (en) 2012-08-20
KR100548120B1 (en) 2006-02-02
HU230154B1 (en) 2015-09-28
SI1174431T1 (en) 2012-09-28
UY25671A1 (en) 2000-03-31
MY138535A (en) 2009-06-30
US6890922B2 (en) 2005-05-10
JP4388729B2 (en) 2009-12-24
CA2395558A1 (en) 1999-05-20
HRP20020585B1 (en) 2013-02-28
US20040067945A1 (en) 2004-04-08
PL340400A1 (en) 2001-01-29
PL201336B1 (en) 2009-03-31
HU227841B1 (en) 2012-05-02
CZ20001759A3 (en) 2000-10-11
DK176852B1 (en) 2009-12-14
US20050070541A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
IL163475A (en) 4-ethoxy-3-(5-methyl-4-oxo-7-propyl-3,4-dihydroimidazo[5,1- f][1,2,4]triazin-2-yl) benzene-sulfonyl chloride, process for its preparation and uses thereof
GB2293201B (en) Side-release buckle having improved locking feature
AU7209098A (en) "Magnesium dichloride-alcohol adducts, process for their preparation and catalyst components obtained therefrom"
NZ306035A (en) 6-substituted pyrazolo[3,4-d]pyrimidine-4-ones and their use
HUT69170A (en) 2-debenzoyl-2-acyl-taxol derivatives and methods for making same, and parmaceutical preparations kontaining them
AU5531596A (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
EP0697179A3 (en) Side-release buckle fastener
EP0775711A4 (en) Peptide having antithrombotic activity and process for producing the same
HUP9800555A3 (en) 3,3-diphenylallylamine derivatives and process for their preparation
GB9610884D0 (en) Multi-purpose attachment for ladies shaver
ZA961909B (en) Process for the preparation of ethyl-N-(2,3-dichloro-6-nitrobenzyl) glycine
KR970000398B1 (en) Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethan and pentafluorethane
PL314948A1 (en) Vehicle safety belt fastener
AU3326895A (en) Cis-hexahydro-5-(2-naphthalenyl)pyrrolo(3,4-c)pyrroles
HU9502305D0 (en) Process for preparation of 1,2,4-triazine-3,5-dionen
AU1944799A (en) Hyperhydrated citicoline, process and use
GR3033299T3 (en) Benzoylguanidines, process for their preparation and medicaments containing them
HUP9600268A1 (en) Herbicidal [1,2,4] thiadiazoles, composition, producing and using them
HK1010052A1 (en) N,N,-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamin]dimaleate salt
GB2304149B (en) Zip fastener
IL113150A0 (en) 1,2,4-triazolo [4,3-a]pyrazin-4-one derivatives and preparation thereof
EP0962475A4 (en) Amidated polyacetals, process for producing the same, and use thereof
MD956F1 (en) N-carboxyaryl-N',N'-dimethylthiouûreas preparation process
GB2296030B (en) Child's safety-belt security
HUP9700628A3 (en) 4-thia-1-aza-bicyclo[3.2.0]heptan-3-imino-2-izopropiliden-7-oxo-beta-lactame derivatives, process for producing them and use of them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
EXP Patent expired